Ballard Spahr filed a false advertising and unfair competition lawsuit Wednesday in Delaware District Court on behalf of Neuronetics Inc., developer of the Neurostar transcranial magnetic stimulation (TMS) device for the treatment of major depressive disorder. The complaint accuses Israel-based Brainsway and its U.S. subsidiary of hyping their competing TMS treatment and making untrue and misleading statements about the plaintiff's Neurostar device. The suit seeks an injunction under the Lanham Act as well as lost profits, disgorgement of Brainsway's profits and other damages. Counsel have not yet appeared for the defendants. The case is 1:22-cv-00626, Neuronetics, Inc. v. Brainsway USA Inc. et al.
Health Care
May 11, 2022, 9:55 AM